Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14551 - 14575 of 15238 in total
Experimental
Antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Investigational
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Investigational
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies...
Investigational
Matched Description: … hip replacement and may protect against renal injury associated with contrast media. ... may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic …
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and
Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.
Investigational
Matched Description: … Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and
ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS.
Investigational
Matched Description: … treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and
Technetium-99m is the metastable isotope of technetium. It is commonly symbolized as 99mTc and used in the area of medical diagnosis. Technetium-99m is the most commonly used medical radioisotope.
Experimental
Matched Description: … It is commonly symbolized as 99mTc and used in the area of medical diagnosis. …
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
Investigational
Matched Description: … cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. …
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
Investigational
Matched Description: … NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and
Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Investigational
Matched Description: … Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability …
NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).
Investigational
Matched Description: … NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies …
V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).
Investigational
Matched Description: … V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 …
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and
Investigational
Matched Iupac: … 11,15}.0^{17,21}]tricosa-1(16),2(10),4(9),5,7,11(15),17,20-octaen-14-one; 4-methylbenzene-1-sulfonic acid
Investigational
Displaying drugs 14551 - 14575 of 15238 in total